We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, CVS Health (CVS - Free Report) closed at $95.93, marking a +1.17% move from the previous day. This change outpaced the S&P 500's 2.65% loss on the day. Elsewhere, the Dow saw a downswing of 1.35%, while the tech-heavy Nasdaq depreciated by 4.18%.
The drugstore chain and pharmacy benefits manager's shares have seen an increase of 8.54% over the last month, surpassing the Medical sector's gain of 3.33% and the S&P 500's gain of 5.47%.
The investment community will be closely monitoring the performance of CVS Health in its forthcoming earnings report. The company's upcoming EPS is projected at $1.85, signifying a 2.21% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $100.18 billion, up 1.28% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $7.44 per share and revenue of $409 billion. These totals would mark changes of +10.22% and +1.72%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for CVS Health. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 4.1% increase. CVS Health presently features a Zacks Rank of #2 (Buy).
Digging into valuation, CVS Health currently has a Forward P/E ratio of 12.75. This indicates a discount in contrast to its industry's Forward P/E of 15.35.
It's also important to note that CVS currently trades at a PEG ratio of 0.93. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical Services stocks are, on average, holding a PEG ratio of 1.46 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 107, placing it within the top 44% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
CVS Health (CVS) Advances While Market Declines: Some Information for Investors
In the latest trading session, CVS Health (CVS - Free Report) closed at $95.93, marking a +1.17% move from the previous day. This change outpaced the S&P 500's 2.65% loss on the day. Elsewhere, the Dow saw a downswing of 1.35%, while the tech-heavy Nasdaq depreciated by 4.18%.
The drugstore chain and pharmacy benefits manager's shares have seen an increase of 8.54% over the last month, surpassing the Medical sector's gain of 3.33% and the S&P 500's gain of 5.47%.
The investment community will be closely monitoring the performance of CVS Health in its forthcoming earnings report. The company's upcoming EPS is projected at $1.85, signifying a 2.21% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $100.18 billion, up 1.28% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $7.44 per share and revenue of $409 billion. These totals would mark changes of +10.22% and +1.72%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for CVS Health. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 4.1% increase. CVS Health presently features a Zacks Rank of #2 (Buy).
Digging into valuation, CVS Health currently has a Forward P/E ratio of 12.75. This indicates a discount in contrast to its industry's Forward P/E of 15.35.
It's also important to note that CVS currently trades at a PEG ratio of 0.93. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical Services stocks are, on average, holding a PEG ratio of 1.46 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 107, placing it within the top 44% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.